Elironrasib may overcome resistance to prior KRAS G12C inhibition in non-small cell lung cancer

Published Date: 23 Oct 2025

Elironrasib led to meaningful and durable responses in patients with metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC), including after prior treatment with KRAS G12C inhibitors and in the presence of features ...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

2.

According to new studies, some cancer patients can safely forego radiation therapy.

3.

According to a study, male testicular cancer risk is linked to neurodevelopmental disorders.

4.

Adding Lenvatinib to Pembro Ups PFS in Head and Neck Cancer

5.

Accelerating the Evidence-Based Integration of Menin Inhibitors Into R/R AML Care: A Live Expert TheraTalk


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot